You’re studying the online version of STAT Well being Tech, our information to how tech is remodeling the life sciences. Sign up to get this newsletter delivered in your inbox each Tuesday and Thursday.
A nudge from AI pinpoints ketamine as a possible uncommon illness remedy
Within the seven troublesome years since their son Mateo was recognized with a uncommon illness known as ANDP syndrome, Victoria Malvagno and Frank Solorzano have been ready for drugs to meet up with their lives. In 2019, the ANDP group received a breakthrough — not from a drug developer, or a health care provider’s workplace, however from a man-made intelligence software. The system, known as mediKanren, sifted by tens of millions of abstracts and quickly pinpointed an sudden goal: ketamine.
The enhance from AI and ketamine’s standing as a repurposed drug allowed the primary levels of analysis to occur in report time. Final month, researchers reported early security outcomes from a research of ketamine in 10 children, together with Mateo, now a rambunctious 13-year-old. However for all of the profit AI introduced, uncommon illness analysis stays difficult, and the subsequent section of the medical trial will likely be extraordinarily expensive. “For us as dad and mom, it could’t occur quick sufficient,” Malvagno instructed Katie. Read more in Katie’s new story.
A primary for ‘synthetic pancreas’ analysis
Synthetic pancreases have been a breakthrough for kind 1 diabetes. Now, extra analysis is getting underway into how the methods — which work by pairing a glucose sensor with an insulin pump to mechanically modify doses of the drug — would possibly assist folks with kind 2 diabetes. This week, a crew of researchers reported outcomes from a trial with 26 sufferers who examined the closed-loop system, all of whom had kind 2 diabetes and wanted dialysis for kidney failure, which might dramatically influence glucose ranges. The system improved the time contributors spent of their goal glucose vary by about 15%; its customers additionally managed to keep away from bouts of extreme low glucose whereas lowering total glucose ranges. Katie has the full story.
Distant care and radiology corporations bag extra funding
- You heard it right here first: radiology software program firm Sirona Medical emerged from stealth with $22.5 million in Collection A funding led by 8VC. It additionally introduced partnerships with 5 U.S. radiology practices to develop RadOS, its radiology working system.
- Cricket Well being, maker of a digital administration software for kidney illness, closed an $83.5 million Collection B spherical led by Valtruis. The spherical additionally included current traders Oak HC/FTand Cigna Ventures.
- Microbiome tech startup DayTwo raised $37 million in a spherical led by Cathay Innovation and aMoon. The corporate additionally appointed a brand new CEO, David Henderson, a former founding govt of Oscar Well being.
DOJ says ‘dangle on a sec’ to United’s acquisition of Change
The U.S. Division of Justice is contemplating a lawsuit blocking UnitedHealth’s $8 billion buy of Change Healthcare and in current weeks, has contacted personal attorneys exterior the division to inquire about main the litigation, The Information reported. First introduced in January, the deal would see the nation’s largest insurer purchase Change Healthcare, a well being IT firm. A number of organizations have expressed opposition to the deal, together with competing insurers and the hospital lobbying group the American Hospital Affiliation.
Chutes & ladders
- Neil Parikh, the previous president of Oscar Well being, joined virtual-first care firm Thirty Madisonas president of medical providers.
- Digital care firm Omada Well beingemployed Steve Prepare dinner, the previous VP and head of strategic finance at One Medical, as CFO.
- Melisa Tucker, who beforehand served as VP of product administration and operations at Flatiron Well being, joined well being care income cycle administration startup Nymas SVP and head of product.
- Digital biology firm Recursion Prescribed drugs employed David Lilienfeld as senior director of security, pharmacovigilance, and epidemiology. Lilienfeld beforehand served as senior director for medical security at Jazz Prescribed drugs, Inc.
What we’re studying